Literature DB >> 10779527

Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function.

T R Faruqi1, E J Weiss, M J Shapiro, W Huang, S R Coughlin.   

Abstract

Thrombin activates protease-activated receptors (PARs) by specific cleavage of their amino-terminal exodomains to unmask a tethered ligand that binds intramolecularly to the body of the receptor to effect transmembrane signaling. Peptides that mimic such ligands are valuable as agonists for probing PAR function, but the tethered ligand peptide for PAR4, GYPGKF, lacks potency and is of limited utility. In a structure-activity analysis of PAR4 peptides, AYPGKF was approximately 10-fold more potent than GYPGKF and, unlike GYPGKF, elicited PAR4-mediated responses comparable in magnitude to those elicited by thrombin. AYPGKF was relatively specific for PAR4 in part due to the tyrosine at position 2; substitution of phenylalanine or p-fluorophenylalanine at this position produced peptides that activated both PAR1 and PAR4. Because human platelets express both PAR1 and PAR4, it might be desirable to inhibit both receptors. Identifying a single agonist for both receptors raises the possibility that a single antagonist for both receptors might be developed. The AYPGKF peptide is a useful new tool for probing PAR4 function. For example, AYPGKF activated and desensitized PAR4 in platelets and, like thrombin, triggered phosphoinositide hydrolysis but not inhibition of adenylyl cyclase in PAR4-expressing cells. The latter shows that, unlike PAR1, PAR4 couples to G(q) and not G(i).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779527     DOI: 10.1074/jbc.M909960199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  A G(i) -independent mechanism mediating Akt phosphorylation in platelets.

Authors:  B Xiang; G Zhang; J Liu; A J Morris; S S Smyth; T K Gartner; Z Li
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

Review 2.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

Review 3.  Protease-activated receptor 4: a critical participator in inflammatory response.

Authors:  Qiang Fu; Jing Cheng; Yebo Gao; Yonglei Zhang; Xiaobing Chen; Jianguo Xie
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

4.  Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist.

Authors:  L Ma; M D Hollenberg; J L Wallace
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

5.  Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents.

Authors:  Steeve Houle; Martin D Papez; Mara Ferazzini; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

6.  Protease activated receptors in cardiovascular function and disease.

Authors:  Junor A Barnes; Shamjeet Singh; Aldrin V Gomes
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

7.  Protease-activated receptors in cancer: A systematic review.

Authors:  Na Han; Ketao Jin; Kuifeng He; Jiang Cao; Lisong Teng
Journal:  Oncol Lett       Date:  2011-04-08       Impact factor: 2.967

8.  The Src family kinases and protein kinase C synergize to mediate Gq-dependent platelet activation.

Authors:  Binggang Xiang; Guoying Zhang; Lucia Stefanini; Wolfgang Bergmeier; T Kent Gartner; Sidney W Whiteheart; Zhenyu Li
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

9.  Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon.

Authors:  F Mulè; R Pizzuti; A Capparelli; N Vergnolle
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 10.  Platelet thrombin receptor antagonism and atherothrombosis.

Authors:  Dominick J Angiolillo; Davide Capodanno; Shinya Goto
Journal:  Eur Heart J       Date:  2009-11-30       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.